A future for CD3 antibodies in immunotherapy of type 1 diabetes
More than 30 years have passed since the first immunotherapy trials in autoimmune insulin-dependent type 1 diabetes were conducted . At this time, it was already apparent, given the compelling observations of the central role of CD4 and CD8 autoreactive T cells in the destruction of insulin-secreting beta-cells, that the immune system of patients would be the most effective drug target, though few tools were available. Small molecule immunosuppressants, such as ciclosporin, were transforming treatment of organ transplant rejection as they proved to be more effective than the conventional therapies, corticosteroids and azathioprine. Based on these observations, ciclosporin was tested in patients with recently diagnosed type 1 diabetes. The results of these first trials provided a fundamental proof-of-concept: that it was possible to effectively treat patients with established hyperglycaemia because, contrary to the prevailing dogma, even after disease diagnosis, a significant mass...
KeywordsAutoimmune diabetes CD3 monoclonal antibodies Immunotherapy T lymphocytes Teplizumab Type 1 diabetes
Autoimmunity-Blocking Antibody for Tolerance
Mixed-meal tolerance test
Programmed cell death 1
The author was the sole contributor to this paper.
Duality of interest
The author has received an honorarium from Provention Bio.
- 11.Nanto-Salonen K, Kupila A, Simell S et al (2008) Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372(9651):1746–1755. https://doi.org/10.1016/S0140-6736(08)61309-4 CrossRefPubMedGoogle Scholar
- 15.Wherrett DK, Bundy B, Becker DJ et al (2011) Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378(9788):319–327. https://doi.org/10.1016/S0140-6736(11)60895-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Herold KC, Gitelman SE, Masharani U et al (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54(6):1763–1769. https://doi.org/10.2337/diabetes.54.6.1763 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53(4):614–623. https://doi.org/10.1007/s00125-009-1644-9 CrossRefPubMedGoogle Scholar
- 25.Herold KC, Gitelman SE, Ehlers MR et al (2013) Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11):3766–3774. https://doi.org/10.2337/db13-0345 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Perdigoto AL, Preston-Hurlburt P, Clark P et al (2018) Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. https://doi.org/10.1007/s00125-018-4786-9
- 36.Patterson CC, Harjutsalo V, Rosenbauer J et al (2018) Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. Diabetologia. https://doi.org/10.1007/s00125-018-4763-3
- 40.Besançon A, Goncalves T, Valette F et al (2018) Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. Diabetologia 61(2):389–398. https://doi.org/10.1007/s00125-017-4459-0 CrossRefPubMedGoogle Scholar